|
|
|
Upsher-Smith Launches Bethanechol Chloride Tablets, USP
Maple Grove MN, June 1, 2005—Upsher-Smith Laboratories,
Inc. has received approval from the FDA to market Bethanechol Chloride
Tablets. Bethanechol Chloride Tablets are indicated for the treatment
of acute postoperative and postpartum non-obstructive (functional)
urinary retention and for neurogenic atony of the urinary bladder
with retention.
Bethanechol Chloride Tablets are an AA-rated, generic
equivalent to the brand name product, Urecholine® (Bethanechol
Chloride) Tablets, USP1. Bethanechol Chloride Tablets
are available in 5mg, 10mg, 25mg and 50mg strengths in 100 count
bottles as well as unit dose.
Bethanechol Chloride Tablets are the latest
addition to the Upsher-Smith product line. In addition to a growing number
of generic alternatives, Upsher-Smith offers quality branded products in
dermatology, cardiology, and women's health.
Visit www.upsher-smith.com or call 1-800-654-2299 to request full prescribing
information.
Upsher-Smith Laboratories,
Inc. is a fully integrated pharmaceutical company that manufactures
and markets prescription pharmaceutical, OTC, and cosmetic products.
Upsher-Smith is also actively involved in licensing innovative compounds
that are in clinical development. For more information about
Upsher-Smith Laboratories, Inc., call 1-800-654-2299 or visit www.upsher-smith.com.
Please See Full Prescribing
Information.
1Urecholine® is a registered trademark
of Odyssey Pharmaceuticals, Inc.
BC09A
|
